TABLE 3.
Clinical outcomes stratified on the development of worrisome features (WFs) or high‐risk stigmata (HRS)
| No development of WF or HRS (n = 669) | Development of WF or HRS (n = 163) | p value | |
|---|---|---|---|
| Follow‐up, months, median (IQR, range) | 39 (41, 12–205) | 48 (59, 12–167) | 0.055 |
| Largest final cyst diameter, mean (SD), mm | 15 (6.6) | 27 (13.2) | <0.001 |
| PDAC, n (%) | 4 (0) | 9 (6) | <0.001 |
| Worrisome features, n (%) | |||
| Cyst size ≥3 cm | ‐ | 91 (56) | ‐ |
| Thickened enhanced cyst walls | ‐ | 18 (11) | ‐ |
| Main pancreatic duct ≥5 mm | ‐ | 49 (30) | ‐ |
| Non‐enhancing mural nodule | ‐ | 16 (10) | ‐ |
| Abrupt PD caliber change with distal atrophy | ‐ | 8 (5) | ‐ |
| Abdominal lymphadenopathy | ‐ | 7 (4) | ‐ |
| High‐risk stigmata, n (%) | |||
| Jaundice | ‐ | 2 (1) | ‐ |
| Enhancing solid component | ‐ | 9 (6) | ‐ |
| Suspicious or positive cytology | ‐ | 5 (3) | ‐ |
| Underwent surgery, n (%) | 3 (0) | 11 (7) | <0.001 |
| PDAC | 0 (0) | 7 (3) | ‐ |
| Moderate‐grade dysplasia | 2 (0) | 4 (2) | ‐ |
| Low‐grade dysplasia | 1 (0) | 0 (0) | ‐ |
| Deceased, n (%) | 24 (4) | 20 (2) | <0.001 |
| PDAC | 2 (0) | 3 (2) | ‐ |
| Other cause | 21 (3) | 17 (10) | ‐ |
| Unknown | 1 (0) | 0 (0) | ‐ |
Abbreviations: HRS, high‐risk stigmata; IQR, interquartile range; PD, pancreatic duct; PDAC, pancreatic ductal adenocarcinoma; SD, standard deviation; WF, worrisome feature.